News | December 07, 2022
Global procalcitonin tests market set to surpass $2 billion in 2030: GlobalData
The use of procalcitonin testing for sepsis management is highest in the US
The use of procalcitonin testing for sepsis management is highest in the US
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The total quantity traded at NSE stood at 34,653 shares and the total turnover stood at Rs. 117.23 lakh.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The move will add new global talent to Cytel’s Strategic Consulting group
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Further, ICAR-IVRI have jointly developed a Lumpy Skin Disease vaccine and as soon as the technology is made available, Hester will acquire the same and manufacture and commercialize the Lumpy Skin disease Vaccine
The companies will leverage their respective proprietary technology platforms
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
Subscribe To Our Newsletter & Stay Updated
